SMSabina E. Munasipova

Sabina E. Munasipova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sabina E. Munasipova has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Multimodal biomarkers of Parkinson’s disease risk in essential tremor. (A prospective cohort study)

    by S.E. Munasipova, Z.A. Zalyalova

    Objective. To identify clinical and neuroimaging biomarkers associated with Parkinson’s disease (PD) onset in patients with essential tremor plus (ET-plus) during prospective observation. Material and methods. This prospective observational cohort study included 159 patients diagnosed with essential tremor (ET), ET-plus, ET-PD, and idiopathic PD. The median observation period was 4.6 years. All participants underwent standardized neurological examinations and assessments, including the Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III), Montreal Cognitive Assessment (MoCA), Scale for the Assessment and Rating of Ataxia (SARA), Unified Dystonia Rating Scale (UDRS), Fahn-Tolosa-Marin Tremor Rating Scale, Non-Motor Symptoms Scale (NMSS), olfactory testing, screening for probable REM sleep behavior disorder (RBD), Stroop test, forward and backward counting tests, Boston Naming Test, literal and semantic verbal fluency tests, transcranial sonography (TCS) of the substantia nigra, and magnetic resonance imaging (MRI) with nigrosome-1 assessment. Results. Conversion from ET-plus to PD occurred in 15 patients. The most significant predictors of conversion were hyperechogenicity of the substantia nigra on transcranial Doppler (TCD), absence of nigrosome-1 on MRI, probable REM sleep behavior disorder (RBD), and ET duration greater than 20 years. The predictive model demonstrated high discriminatory power (C-statistic 0.89). Clinically, patients who converted showed a combination of non-motor symptoms, cognitive decline, signs of nigrostriatal dysfunction, and more frequent resting tremor. Conclusions. The risk of Parkinson’s disease onset in patients with ET-plus is determined by a combination of multimodal biomarkers. The prospective identification of 15 patients who converted supports classifying this subgroup as a high-risk phenotype that warrants ongoing monitoring and comprehensive evaluation.

  • Tremor-dominant form of Parkinson’s disease

    by Z.A. Zalyalova, E.A. Katunina, D.V. Pokhabov, S.E. Munasipova, M.M. Ermakova

    The article is of a review nature and is devoted to tremor, one of the maladaptive and difficult-to-treat symptoms of Parkinson’s disease (PD). Along with the classic rest tremor, patients with PD may experience tremor of other modalities: postural tremor, kinetic tremor, which reflects a multimodal mechanism of tremor formation involving multiple neurotransmitter systems. The unpredictable response to therapeutic options, the ambiguous response to levodopa, also reflects the role of multiple underlying pathophysiological processes. Among the drug methods of tremor correction, preference is given to dopamine receptor agonists — due to the spectrum of their pharmaceutical action, high efficiency in relation to all leading motor and a number of non-motor manifestations. The evidence for advanced neurosurgical, non-invasive modalities is mixed, and there are insufficient comparative studies to assess their efficacy in patients with tremor-dominant forms of PD.


  • Neuro-cognitive features of essential tremor plus

    by Kazan State Medical University, Z. A. Zalyalova, M. M. Ermakova, S. E. Munasipova, D. M. Khasanova, Republic Consultative-Diagnostic Center For Extra-Pyramid Pathology And Botulin Therapy — Hospital For Military Veterans

    Essential tremor (ET) is the most common movement disorder, the main manifestation of which is progressive postural-kinetic trembling of the limbs, its pattern most often involving the hands. Recent data indicate a higher frequency of ET in combination with various neurological symptoms, which in the new classification is usually classified as essential tremor plus (ET+). The purpose is to identify and determine the characteristics of intragroup division and changes in neurocognitive status among various forms of ET+ in comparison with ET patients. Material and methods. At the Republic Consultative-diagnostic Center for extra-pyramid pathology and botulin therapy in Kazan, a prospective study was carried out on 116 patients with essential tremor, using clinical, anamnestic and statistical methods of data collection and analysis. Results. Neurocognitive phenotypic variants of ET have been established. It has been proven that all patients with ET, even in the absence of a global decline in intelligence, are characterized by changes in attention, speech fluency, memory, and executive functions; dementia was detected in 28% of patients included in the study. For a reliable diagnosis of ET, in addition to assessing the standard neurological status, it is necessary to assess the severity of tremor using the FTM scale, assessing ataxia using the SARA scale, and assessing the cognitive status using the MOCA test.

  • Multiple subtypes of tremor-dominant form of Parkinson’s disease: diagnostic and therapeutic significance

    by Kazan State Medical University, Z. A. Zalyalova, S. E. Munasipova, M. M. Ermakova

    Tremor is one of the most common motor symptoms in Parkinson’s disease (PD) and affects up to 75% of patients. The tremolous form of PD is heterogeneous in clinical manifestations. Along with classic rest tremor, patients with PD may experience postural and kinetic types of the tremor, which reflects the multimodal mechanism of its formation. Classifications of PD are constantly changing, including within the tremor-dominant form. The varied responses to levodopa also reflect the role of multiple underlying pathophysiological processes. New, non-antiparkinson drugs are being studied. Evidence of the effectiveness of advanced neurosurgical, non-invasive treatment methods is not always convincing; there are no large-scale comparative studies assessing their effectiveness in patients with tremor-dominant forms of PD.

  • Etiological and pathogenetic mechanisms of forming muscle dystonias

    by Kazan State Medical University, S. E. Munasipova, Z. A. Zalyalova, A. A. Terekhova

    This article discusses the issues of muscular dystonia pathogenesis that are relevant to modern medicine, as well as the possibility of using the pathogenetic concept as a substrate to supplement the classification criteria. Reviewing the international publications on etiopathophysiology, genetics and classification, the article summarizes the main mechanisms for the occurrence of a pathological process at different levels of the nervous system. Despite the frequent clinical similarity of the symptoms of various forms of muscular dystonia, these symptoms may be the result of dysfunction of completely different genetic and neurophysiological mechanisms. The article focuses on the importance of studying the etiological and pathogenetic mechanisms and their further implementation in clinical practice in order to develop more accurate treatment techniques aimed at eliminating the specific causes of the development of specific forms of muscular dystonia.


  • Open Access

    A “new” role of amantadines in COVID-19 in patients with Parkinson’s disease: results of own comparative study

    by Z. A. Zalyalova, S. E. Munasipova, D. M. Khasanova, G. R. Ilyina, Z. G. Khayatova, N. I. Bagdanova

    A “new” role of amantadines in COVID-19 in patients with Parkinson’s disease: results of own comparative study

  • Frontotemporal dementia with cortico-basal syndrome

    by Z.A. Zalyalova, S.E. Munasipova

    FTD is a group of neurodegenerative diseases with progressive deterioration of behavioral and speech disorders, morphologically associated with pathology of the frontal or temporal lobes. International clinical trials have made it possible to define modern diagnostic criteria for various subtypes of clinically «possible/probable» FTD. Our article is devoted to one of the rare subtypes of frontotemporal dementia (FTD), corticobasal syndrome (CBD), in which we presented a review of current data with a demonstration of clinical observation. A clinical case of a patient with a patient with speech disorders and memory impairment is presented. A 60-year-old man at the time of the outpatient visit had been complaining of speech impairment for two years, a slight decrease in memory for current events. Neurological and neuropsychological studies revealed two leading clinical syndromes in the patient: «frontal» syndrome with impaired higher cortical functions in the form of efferent motor aphasia, impaired writing and reading with visual-spatial agnosia and dysgraphia, «frontal» signs (positive «palm-mouth «and» grasping «reflexes); «Corticobasal syndrome» with pronounced dynamic, optic-kinesthetic dyspraxia, dermolexia, apraxia of closing the eyes, «alien» hand syndrome with symptoms of levitation and intermanual conflict. MRI diagnostics revealed changes characteristic of neurodegeneration of the frontotemporal type (atrophy of the frontal and temporal lobes prevails). Taking into account complaints, anamnesis of the disease, identified clinical syndromes and structural changes according to MRI data, the patient was diagnosed with a clinically «probable» FTD. Determination and accurate diagnosis of FTD subtypes will help the neurologist in managing these patients with the appointment of the correct pharmacologic treatment. In FTD, in contrast to AD patients, the administration of cholinesterase inhibitors does not lead to a positive therapeutic effect a positive therapeutic effect and, therefore, is not advisable. The standards of patient therapy should include recommendations for antipsychotic therapy, the use of antidepressants (SSRIs) and anxiolytics with nootropic effects for the correction of affective and behavioral disorders.


  • Open Access

    Clinical and Epidemiological Aspects of Huntington Disease in the Republic of Tatarstan

    by Sabina E. Munasipova, Zuleykha A. Zalyalova, Залялова Зулейха Абдуллазяновна

    His study aimed to evaluate the epidemiological features ofHuntington disease (HD), based on data from the Centre for Extrapyramidal Pathology and Botulinum Toxin Therapy of theRepublic ofTatarstan. Materials and methods. We examined 44 patients with HD (mean age 47.3 ± 12.5 years). The study design included determining and comparing clinical data, genealogical and epidemiological data, and laboratory parameters. Results. The highest prevalence of HD was found in the north-western and north-eastern parts of theRepublic ofTatarstan being 1.1 per 100,000 people, regardless of nationality. The phenomenon of anticipation in HD inheritance was observed, considering the instability and increasing expansion in subsequent generations along the paternal line. Psychiatric manifestations (apathy, irritability, anxiety, depression) were present in 61.4% of cases at disease onset. One male patient was presumably diagnosed with the Westphal variant. Manifest carriers of a CAG-expansion in the range of 36–39 repeats in the mutant gene were found in 15.9% of cases and were predominantly represented by females (85.7%).